论文信息 - Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. - 字舞流文

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

S. Paik | J. Costantino | C. Geyer | D. Wickerham | N. Wolmark | K. Pogue-Geile | S. Swain | Seong-Rim Kim | E. Mamounas | Jong-Hyeon Jeong | L. Fehrenbacher | P. Rastogi | N. Song | Nicole L Blackmon | P. Gavin | Melanie Finnigan | Nicole L. Blackmon